Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.66 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19879791 | 1.00 | GLP1R (0.66) | GLP1RNOD1FOLH1PLA2G10 | |
| SCHEMBL10046212 | 1.00 | GLP1R (0.66) | GLP1RNOD1FOLH1PLA2G10 | |
| SCHEMBL12981754 | 1.00 | GLP1R (0.66) | GLP1RNOD1FOLH1PLA2G10 | |
| SCHEMBL15896588 | 1.00 | GLP1R (0.66) | GLP1RNOD1FOLH1PLA2G10 | |
| SCHEMBL24983192 | 0.99 | GLP1R (0.68) | GLP1RNOD1FOLH1PLA2G10 | |
| SCHEMBL21754511 | 0.94 | GLP1R (0.69) | GLP1RNOD1 | |
| SCHEMBL16182576 | 0.94 | GLP1R (0.72) | GLP1RNOD1 | |
| SCHEMBL17244046 | 0.94 | GLP1R (0.72) | GLP1RNOD1 | |
| SCHEMBL16182577 | 0.94 | GLP1R (0.72) | GLP1RNOD1 | |
| SCHEMBL10315877 | 0.94 | GLP1R (0.72) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023217744-A1 | PRODRUGS OF GLP-1 POLYPEPTIDE AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-11-16 | — | — | WO | disclosed |
| US-11649269-B2 | Bifunctional compounds comprising insulin peptides and EGF(A) peptides | NOVO NORDISK A/S (DK) | 2023-05-16 | — | — | US | disclosed |
| US-11649269-B2 | Bifunctional compounds comprising insulin peptides and EGF(A) peptides | NOVO NORDISK A/S (DK) | 2023-05-16 | — | — | US | disclosed |
| US-9480753-B2 | FGF21 derivatives with albumin binder A-B-C-D-E- and their use | NOVO NORDISK A/S (DK) | 2016-11-01 | — | — | US | disclosed |
| US-9480753-B2 | FGF21 derivatives with albumin binder A-B-C-D-E- and their use | NOVO NORDISK A/S (DK) | 2016-11-01 | — | — | US | disclosed |
| US-9181305-B2 | Exendin-4 peptide analogues | SANOFI (FR) | 2015-11-10 | — | — | US | disclosed |
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2013-06-06 | — | — | US | disclosed |
| US-20130096055-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2013-04-18 | — | — | US | disclosed |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | NOVO NORDISK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143798-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GCG, IAPP | GLP1R 1/4885NOD1 1083/4885FOLH1 251/4885 |
| US-11649269-B2 | Bifunctional compounds comprising insulin peptides and EGF(A) peptides | IAPP, IGFBP1, IGFBP2 | GLP1R 16/4885NOD1 2091/4885FOLH1 659/4885 |
| US-20130096055-A1 | LONG-ACTING Y2 RECEPTOR AGONISTS | NPY2R, NPY1R, NPY5R | GLP1R 5/4885NOD1 3136/4885FOLH1 1335/4885 |
| US-20100216715-A1 | FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use | FABP1, FABP4, FGFR1 | GLP1R 45/4885NOD1 1001/4885FOLH1 1037/4885 |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 295/4885FOLH1 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.